Skip to content

Randomized Controlled Study Evaluating Genicular Artery Embolization Against Intra-Articular Corticosteroid Knee Injection for Osteoarthritic Knee Pain

Resorbable Embolization MicroSpheres for OsteoaRthritis Benefit

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06872567
Acronym
RESORB
Enrollment
126
Registered
2025-03-12
Start date
2025-10-01
Completion date
2026-12-31
Last updated
2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee Osteoarthritis (Knee OA)

Brief summary

Multi-center, prospective, randomized trial of GAE using Nexsphere-F against steroid injection

Interventions

genicular artery embolization

DRUGCorticosteroid Injection

Corticosteroid Injection

Sponsors

Next Biomedical Co., Ltd.
CollaboratorINDUSTRY
North American Science Associates Ltd.
Lead SponsorNETWORK

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient has localized knee pain * Must be an appropriate candidate for arterial vascular access procedure

Exclusion criteria

* Known sensitivity or allergy to implant materials * Unable or unwilling to comply with study requirements

Design outcomes

Primary

MeasureTime frameDescription
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)6 and 12-month post treatmentChanges in total Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score. Scale ranges from 0 to 96 with higher scores equating to greater pain, stiffness and difficulty with activities of daily living.
Serious Adverse Events (SAE)Treatment, 1,3,6,9 and 12-month post treatment

Secondary

MeasureTime frameDescription
WOMAC total score9 month post treatmentChanges in total Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score. Scale ranges from 0 to 96 with higher scores equating to greater pain, stiffness and difficulty with activities of daily living

Countries

United States

Contacts

Primary ContactZiv J Haskal, MD
haskalembo@gmail.com16463691570

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026